No difference in plasma or urinary F2-isoprostanes among patients with Huntington's disease or Alzheimer's disease and controls [3]

Annals of Neurology

Volumn 48, Issue 6, 2000, Pages 950-

  Montine, T J ^a   Shinobu, L ^b   Montine, K S ^a   Roberts II, L J ^a   Kowall, N W ^b   Beal, M F ^b   Morrow, J D ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN F2 ISOPROSTANE; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ANALYTIC METHOD; BLOOD LEVEL; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUNTINGTON CHOREA; LETTER; MASS SPECTROMETRY; OXIDATIVE STRESS; PRIORITY JOURNAL; QUANTITATIVE ASSAY; URINE LEVEL;

AGED; ALZHEIMER DISEASE; DINOPROST; HUMANS; HUNTINGTON DISEASE; MIDDLE AGED;

EID: 0033663880     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(200012)48:6<950::AID-ANA23>3.0.CO;2-F     Document Type: Letter

References (5)

1. Cerebrospinal fluid F2-isoprostanes are elevated in Huntington's disease
2. 2-isoprostane concentration in probable Alzheimer's disease
3. 2-isoprostane levels are increased in Alzheimer's disease: Evidence of increased oxidative stress in vivo
4. Plasma levels of 8-epiPGF2alpha, an in vivo marker of oxidative stress, are not affected by aging or Alzheimer's disease
5. 2-isoprostanes) in smokers